Hang Seng Index: +1.40% (+340.37 points), closed at 24,681.1 points, hitting a new one-month high since mid-June, marking the fourth consecutive day of gains.
Range: Low 24449.53 / High 24774.84, oscillated upward throughout the day, with gains slightly narrowing at the close.
Total Turnover: 304.297 billion HKD, turnover remained high, capital activity stable.
Hang Seng Tech Index: +1.30% (+61.03 points), closed at 4740.49 points.
Turnover 83.36 billion, heavyweight internet and AI application stocks strengthened in sync.
Hang Seng China Enterprises Index: +1.00%, closed at 8184.38 points.
Southbound Capital: Net purchase of 13.364 billion HKD for the day, mainland capital continued to add positions, serving as the core funding source supporting the index today.
Market Structure: Among 93 HSI constituents, 68 rose and 21 fell, a broad rally pattern with significant structural divergence.
Core Drivers of Today's Rally (Dual Internal & External Logic)
(1) Easing Overseas Liquidity (Primary External Catalyst)
US June inflation data came in below expectations, market probability of a Fed rate hike in July plummeted from over 40% to around 20%, US 10-year Treasury yield fell 10bp, USD weakened:
Global risk appetite recovered, foreign capital flowed back into Hong Kong stocks and Chinese ADRs;
Pressure on Hong Kong stock valuations from high US Treasury yields eased temporarily;
Market downplayed Middle East geopolitical conflict disturbances, capital prioritized trading on improved liquidity logic.
(2) Mainland Policy + Industry Catalysts (Internal Main Theme)
Pharmaceutical Policy Dividends Materialize
Three ministries issued the "2026 Edition National Essential Drug List," expanding the inclusion scope for innovative drugs, confirming an industry policy inflection point; coupled with multiple pharma companies issuing better-than-expected positive profit alerts / large overseas licensing deals:
Joinn Laboratories (06127): H1 net profit forecast to surge 884%~1377%, surged 23.78%;
Innovent Biologics (01801): $1.1 billion overseas licensing deal, rose 7.77%;
CRO, innovative drugs, biologics all strengthened, becoming today's strongest theme.
AI Industry Event Catalysts
Shanghai World Artificial Intelligence Conference opens on July 17, market front-runs speculation on AI application and large model targets:
MINIMAX rose over 13%, Zhipu AI rose over 6%, computing power and software application sectors saw concentrated capital; institutions are optimistic about accelerated commercialization of domestic large models.
Hong Kong Capital Market Policy Support
Earlier policies like the central bank releasing offshore RMB liquidity, foreign reserves increasing allocation to Hong Kong assets, Bond Connect expansion continue to take effect; foreign institutions (Goldman Sachs, Morgan Stanley) raised Hong Kong stock valuation targets, expectations for long-term capital entry warmed.
IMF raised China's full-year GDP forecast to 4.6%, confirming manufacturing and export resilience, offsetting Q2 GDP slowdown concerns, boosting confidence in Chinese assets.
【Three Major Leading Themes】
Biopharma (Strongest Across the Board)
CRO, innovative drugs, biologics CDMO all surged, driven by: new essential drug list + explosive earnings growth + large overseas licensing, representing a capital rotation theme of low valuation + fundamental reversal; the pharma sector significantly underperformed the broader market earlier this year, seeing concentrated catch-up today.
Representatives: Joinn Laboratories, Wuxi Biologics, Innovent Biologics, WuXi XDC.
Large Internet Tech Heavyweights
Dual valuation repair from domestic demand + AI businesses, contributing major index gains:
Meituan - W (03690) +5.3%: Expectations for local consumption recovery, food delivery profitability continues to optimize;
Tencent Holdings (00700) +3.9%: Games, advertising recovery, AI cost reduction and efficiency improvement;
Lenovo Group +4.7%, Alibaba, Kuaishou also rose.
Chinese Brokers + Consumer Retail
Brokers: CICC +5%, GF Securities, Galaxy Securities rose over 4%, benefiting from improved market turnover and Hong Kong stock valuation repair;
Consumer: MINISO +7%, offline consumption, overseas retail sentiment improved.
【Underperforming Sectors (Profit-Taking)】
Previously Hot Cycle Resources
Gold, PCB copper clad laminates, lithium stocks saw profit-taking at highs: Lingbao Gold, Dingtai High-Tech fell over 5%, Ganfeng Lithium -4%, Tianqi Lithium -3%; logic being excessive previous gains, capital switching to low-priced pharma and AI software.
Some Semiconductor Hardware
SMIC -2.62%, Hua Hong Semiconductor weakened, capital shifted from upstream AI hardware to AI applications and pharma, internal sector rotation from high to low.
A few insurance and traditional property heavyweights slightly dragged on the index.
IV. Capital and Sentiment Deep Dive
Mainland Capital Dominates Market
Southbound net inflow of tens of billions daily, mainland capital prefers pharma and internet leaders; foreign capital mainly saw small net inflows, cautious in pace, awaiting further Fed commentary.
Rotation Characteristics Evident
Capital flowed out from AI hardware and gold cyclical stocks hyped in H1, into oversold pharma, AI software, and consumer internet. The market entered a phase of rotation between high and low valuations, ending the broad rally in single themes.
Short-Term Pressure Emerges
HSI approached the 50-day moving average resistance at 24813 points, today's high of 24774 met resistance and retreated. Short-term 24800 is a key bull-bear dividing line. After four consecutive days of gains, short-term profit-taking pressure accumulated, creating a need for consolidation and pullback.
Short-selling data steady, no large-scale short position increases, market panic sentiment low.$Hang Seng Index(00HSI.HK)